PMID- 9106263
OWN - NLM
STAT- MEDLINE
DCOM- 19970724
LR  - 20190831
IS  - 0197-0186 (Print)
IS  - 0197-0186 (Linking)
VI  - 30
IP  - 4-5
DP  - 1997 Apr-May
TI  - Additive effects of basic fibroblast growth factor and phorbol ester on 
      beta-amyloid precursor protein expression and secretion.
PG  - 475-81
AB  - Expression of the beta-amyloid precursor protein (beta-APP), a proteoglycan whose 
      proteolytically derived fragments have been implicated in the neuropathology 
      observed in Alzheimer's disease, is regulated by a variety of stimuli including 
      cytokines, phorbol esters, and growth factors. In this study we report the 
      effects of basic fibroblast growth factor (bFGF) and the protein kinase C 
      activator, phorbol 12-myristate 13-acetate (PMA), on beta-APP expression and 
      secretion in SKNMC human neuroblastoma cells. Treatment of the cells with bFGF 
      for 24 h increased APP promoter activity 200%, cell-associated full-length 
      protein 189%, and secreted amino-terminal fragments 192% compared to basal 
      levels. Treatment of the cells with PMA for 24 h also up-regulated APP expression 
      and secretion with increases of 170, 112, and 161% being observed for promoter 
      activity, cell-associated full-length protein, and secreted amino-terminal 
      fragments, respectively. The effects of bFGF and PMA on the expression and 
      secretion of beta-APP were additive and distinct in that: (a) co-treatment of the 
      cells with maximally stimulating doses of bFGF and PMA had an additive effect on 
      both induced full-length protein expression (242%) and secretion of 
      amino-terminal fragments (311%) compared to basal levels; (b) net levels of 
      full-length protein expression and secretion induced by bFGF and PMA differed 
      significantly from each other; and (c) down-regulation of phorbol 
      ester-stimulated protein kinase C by pre-treatment of the cells for 24 h with 1 
      microM PMA failed to attenuate bFGF-induced transcription or induced secretion of 
      beta-APP.
FAU - Ringheim, G E
AU  - Ringheim GE
AD  - Neuroscience Therapeutic Area, Hoechst Marion Roussel Inc., Bridgewater, NJ 
      08807-0800, USA.
FAU - Aschmies, S
AU  - Aschmies S
FAU - Petko, W
AU  - Petko W
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurochem Int
JT  - Neurochemistry international
JID - 8006959
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Carcinogens)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Amyloid beta-Protein Precursor/*metabolism
MH  - Blotting, Western
MH  - Carcinogens/*pharmacology
MH  - Drug Synergism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibroblast Growth Factor 2/*pharmacology
MH  - Humans
MH  - Neuroblastoma/metabolism
MH  - Tetradecanoylphorbol Acetate/*pharmacology
MH  - Tumor Cells, Cultured
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1016/s0197-0186(96)00084-8 [doi]
PST - ppublish
SO  - Neurochem Int. 1997 Apr-May;30(4-5):475-81. doi: 10.1016/s0197-0186(96)00084-8.